Related Experiment Video

Updated: May 22, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity

Hae Chang Jeong1, Youngkeun Ahn, Young Joon Hong

  • 1Chonnam National University Hospital, Gwangju, South Korea.

International Journal of Cardiology
|May 18, 2012
PubMed

Insights

Statin therapy reduced stent thrombosis risk in acute myocardial infarction patients with high hs-CRP levels. This benefit was most pronounced in specific high-risk subgroups, indicating targeted statin use may be beneficial.

Area of Science:

  • Cardiology
  • Biomarkers
  • Pharmacotherapy

Background:

  • Stent thrombosis (ST) remains a critical complication following coronary stent implantation in acute myocardial infarction (AMI) patients.
  • High-sensitivity C-reactive protein (hs-CRP) is a marker of inflammation and a predictor of cardiovascular events.
  • The role of statin therapy in mitigating ST risk, particularly in relation to hs-CRP levels, requires further elucidation.

Purpose of the Study:

  • To investigate the association between statin therapy, hs-CRP levels, and the risk of early stent thrombosis (ST) in patients with acute myocardial infarction (AMI).
  • To determine if peri-procedural statin treatment modifies the risk of ST in AMI patients stratified by hs-CRP levels.

Main Methods:

  • Analysis of 9,162 AMI patients from the Korean Acute Myocardial Infarction Registry who underwent coronary stent implantation.
  • Stratification of patients into four groups based on hs-CRP levels (≤ 2.0 mg/L or >2 mg/L) and peri-procedural statin treatment.
  • Comparison of early ST incidence across these groups, including multivariable Cox regression analysis.

Main Results:

  • Statin therapy did not significantly impact early ST in patients with low hs-CRP levels.
  • In patients with high hs-CRP levels, statin treatment significantly reduced the incidence of early ST.
  • Subgroup analysis within the high hs-CRP group indicated greater benefit from statins in younger patients (<65 years), those without diabetes, with high BMI, and high Killip class.
  • Lack of statin therapy was identified as a significant predictor of ST in high hs-CRP patients.

Conclusions:

  • Peri-procedural statin treatment is associated with a reduced incidence of early stent thrombosis in acute myocardial infarction patients presenting with high hs-CRP levels.
  • These findings suggest that statin therapy may be particularly beneficial for high-risk AMI patients with elevated inflammatory markers.
Abstract

Keywords:
InflammationMyocardial infarctionStatinsStentsThrombosis

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...